AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05023252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
Study NCT05610176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amvia Sky pacemaker or CRT-P device
Description: Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
Study NCT04662541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Integrated Health (MIH)
Description: MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.
Study NCT04662541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transitions of care coordinator (TOCC)
Description: The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
Study NCT06535750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
Study NCT04733560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
Study NCT04733560 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Pudendal nerve block
Description: Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
Study NCT04733560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injectable Product
Description: Used for pudendal nerve block in the intervention arm
Study NCT06577376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib tablets
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
Study NCT06577376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposomes
Description: A chemotherapy
Study NCT06577376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel or docetaxel or irinotecan
Description: Paclitaxel or docetaxel or irinotecan is used as a control.
Study NCT06648889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.
Study NCT06648889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
Study NCT06091774 — intervention group
Intervention type: DEVICE
Intervention: CHD therapy through iATROS medical device
Description: The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
Study NCT05394142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator arm with placebo
Study NCT05394142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 7.5 mg/day
Study NCT05394142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 50 mg/day
Study NCT05394142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg/day
Study NCT04667117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
Study NCT04667117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine
Description: 2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
Study NCT04667117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab.
Study NCT04667117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iDMT
Description: Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
Study NCT04937374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehmannia glutinosa leaf extract
Description: One capsule to be taken after breakfast.
Study NCT04937374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose (MCC)
Description: One capsule to be taken after breakfast.
Study NCT03832127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fludarabine
Description: Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
Study NCT05800392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC103
Description: The intervention is composed by two medications: An active sublingual pill and an active oral one.
Study NCT05800392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DEC103
Description: The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
Study NCT05771831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes®
Description: The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
Study NCT06078085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation program
Description: The rehabilitation program is created by a physical therapist
Study NCT05771831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard platelet concentrate
Description: The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).
Study NCT06524960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
Study NCT06524960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
Study NCT05550584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).
Description: In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
Study NCT05550584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA
Description: Mechanical ventilation performed by a laringeal mask
Study NCT06649981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMT capsule
Description: A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population.
Study NCT06649981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s)
Description: A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results.
Study NCT04688983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponatinib
Description: 30 mg QD starting day 1, given continuously unless interruption required for toxicity
Study NCT04688983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 30 mg QD starting day 1, given continuously unless interruption required for toxicity
Study NCT04688983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
Study NCT04688983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: starting day 1, given orally at 400mg BID continuously for 8 weeks
Study NCT06450275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG Film Coated Tablet
Description: 1 tablet of Dolutegravir 50mg film-coated tablets
Study NCT06450275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tivicay 50mg, film-coated tablets
Description: 1 tablet of Dolutegravir 50mg film-coated tablets
Study NCT05128942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
Study NCT05672992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spatial-frequency domain imaging (SFDI)
Description: SFDI is a method using near-infrared (NIR) light to generate wide field images (>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
Study NCT05672992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spatial-frequency domain imaging (SFDI)
Description: SFDI is a method using near-infrared (NIR) light to generate wide field images (>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
Study NCT04974216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
Study NCT04974216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
Study NCT04974216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administration: IV at 375mg/m2 C1 to C6: D1
Study NCT05688904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Topical 4% Imipramine
Study NCT05688904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT06198569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF EXERCISES
Description: Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization
Study NCT06198569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strength exercises
Description: Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights
Study NCT04749719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remotely supervised transcranial direct current stimulation
Description: Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
Study NCT04749719 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: remotely supervised transcranial direct current stimulation
Description: Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
Study NCT05213936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling with hairstyle
Description: Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
Study NCT05213936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling with conditioner and water emulsion
Description: Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
Study NCT05873413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivate-the-Bystander
Description: A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
Study NCT05873413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivate-the-Bystander+Alcohol
Description: A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
Study NCT05873413 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-only Control
Description: A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
Study NCT05546996 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FlowSense
Description: Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin >3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis.
Study NCT04980053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Intervention group Control group
Study NCT05796570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Nucleoside metabolic inhibitor, via IV infusion.
Study NCT05796570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
Study NCT06516757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boric Acid Suppository
Description: Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
Study NCT05316038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
Study NCT05794464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation and/or electrical cardioversion
Description: Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
Study NCT04598477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
Study NCT04598477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral prednisone tablets
Study NCT05892679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks.
Study NCT05496582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT04597320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer.
Study NCT04597320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer.
Study NCT04597320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.